Flestolol sulfate | CAS# 88844-73-9 | Beta-receptor

MedKoo Cat#: 571483 | Name: Flestolol sulfate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Flestolol sulfate is an anti-adrenergic beta-receptor that produces several hemodynamic changes. These changes include a reduction in heart rate, rate pressure product, and increase in peripheral vascular resistance, as well as decrease in myocardial contractility. It is fast-acting with a short half-life.

Chemical Structure

Flestolol sulfate

CAS#88844-73-9

Theoretical Analysis

MedKoo Cat#: 571483

Name: Flestolol sulfate

CAS#: 88844-73-9

Chemical Formula: C15H24FN3O8S

Exact Mass:

Molecular Weight: 425.43

Elemental Analysis: C, 42.35; H, 5.69; F, 4.47; N, 9.88; O, 30.09; S, 7.54

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Flestolol sulfate; ACC9089; ACC-9089; ACC 9089

IUPAC/Chemical Name

Benzoic acid, 2-fluoro-, 3-((2-((aminocarbonyl)amino)-1,1-dimethylethyl)amino)-2-hydroxypropyl ester, (+-)-, sulfate (1:1) (salt)

InChi Key

QLCLNERFMKNCBZ-UHFFFAOYSA-N

InChi Code

InChI=1S/C15H22FN3O4.H2O4S/c1-15(2,9-18-14(17)22)19-7-10(20)8-23-13(21)11-5-3-4-6-12(11)16;1-5(2,3)4/h3-6,10,19-20H,7-9H2,1-2H3,(H3,17,18,22);(H2,1,2,3,4)

SMILES Code

O=C(OCC(O)CNC(C)(C)CNC(N)=O)C1=CC=CC=C1F.O=S(O)(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 425.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Strom J, Josephson M, Frishman WH, Singh B, Heilbrunn S, Osterle S, Turlapaty P, Viray R, Coe J, Bell V, et al. Hemodynamic effects of flestolol, a titratable short-acting intravenous beta-adrenergic receptor blocker. J Clin Pharmacol. 1988 Mar;28(3):276-82. PubMed PMID: 2896204. 2: Achari R, Drissel D, Hulse JD, Bell V, Turlapaty P, Laddu A, Matier WL. Pharmacokinetics and pharmacodynamics of flestolol, a new short-acting, beta-adrenergic receptor antagonist. J Clin Pharmacol. 1987 Jan;27(1):60-4. PubMed PMID: 2890664. 3: Swerdlow CD, Peterson J, Liem LB. Effect of flestolol on ventricular rate during atrial fibrillation in Wolff-Parkinson-White syndrome. Am J Cardiol. 1988 Jul 1;62(1):78-82. PubMed PMID: 2898208. 4: Swerdlow CD, Peterson J, Turlapaty P. Clinical electrophysiology of flestolol, a potent ultra short-acting beta blocker. Am Heart J. 1986 Jan;111(1):49-53. PubMed PMID: 2868646. 5: Grohs JG, Fischer G, Raberger G. Effects of flestolol, an ultra-short acting beta-adrenoceptor antagonist, on hemodynamic changes produced by treadmill exercise or isoprenaline stimulation in conscious dogs. J Cardiovasc Pharmacol. 1990 Feb;15(2):175-81. PubMed PMID: 1689410. 6: Fischer G, Grohs JG, Raberger G. Verification of a canine model of transient exercise induced myocardial dysfunction: antianginal effects of flestolol, an ultra short acting beta adrenoceptor antagonist. Cardiovasc Res. 1990 Feb;24(2):115-20. PubMed PMID: 1970278. 7: Murthy VS, Hwang TF, Rosen LB, Gorczynski RJ. Controlled beta-receptor blockade with flestolol: a novel ultrashort-acting beta-blocker. J Cardiovasc Pharmacol. 1987 Jan;9(1):72-8. PubMed PMID: 2434798. 8: Reynolds RD, Brown BS. Antiarrhythmic activity of flestolol, a novel ultra-short-acting beta-adrenoceptor antagonist, in the dog. Eur J Pharmacol. 1986 Nov 12;131(1):55-66. PubMed PMID: 2880726. 9: Achari R, Hulse JD, Drissel D, Matier WL. Pharmacokinetics of flestolol in man: preliminary data. Br J Clin Pharmacol. 1985 Dec;20(6):691-4. PubMed PMID: 2868745; PubMed Central PMCID: PMC1400830. 10: Swerdlow C, Peterson J, Liem LB, Blake K, Franz MR, Laddu A. Electropharmacology of flestolol for supraventricular tachycardia without associated structural heart disease. Am J Cardiol. 1987 Nov 1;60(13):1055-60. PubMed PMID: 2890290. 11: Steinberg JS, Katz RJ, Somberg JC, Keefe D, Laddu AR, Burge J. Safety and efficacy of flestolol, a new ultrashort-acting beta-adrenergic blocking agent, for supraventricular tachyarrhythmias. Am J Cardiol. 1986 Nov 1;58(10):1005-8. PubMed PMID: 2877563. 12: Turlapaty P, Burge J, Hulse J, Achari R, Bell V, Mosberg H, Laddu A. Tolerance and beta-adrenergic blocking activity of flestolol, a short-acting beta blocker. Clin Pharmacol Ther. 1986 May;39(5):543-9. PubMed PMID: 3698462. 13: Todt H, Krumpl G, Krejcy K, Raberger G. Effects of beta-adrenoceptor antagonism upon delayed reperfusion arrhythmias in conscious dogs. Eur J Pharmacol. 1991 Apr 17;196(2):109-15. PubMed PMID: 1678714. 14: Stampfli HF, Quon CY. Polymorphic metabolism of flestolol and other ester containing compounds by a carboxylesterase in New Zealand white rabbit blood and cornea. Res Commun Mol Pathol Pharmacol. 1995 Apr;88(1):87-97. PubMed PMID: 7620841. 15: Quon CY, Stampfli HF. Biochemical characterization of flestolol esterase. Res Commun Chem Pathol Pharmacol. 1993 Sep;81(3):309-22. PubMed PMID: 8235065. 16: Moore P, Mai K, Lai CM. Quantitation of the ultra short acting beta-adrenergic antagonist flestolol in blood by liquid chromatography. J Pharm Sci. 1986 Apr;75(4):424-6. PubMed PMID: 2873234. 17: Barton SD, Burge J, Turlapaty P, Laddu AR. Flestolol: an ultra-short-acting beta-adrenergic blocking agent. J Clin Pharmacol. 1986 Mar;26 Suppl A:A36-A39. PubMed PMID: 2870085. 18: Potter PM, Wadkins RM. Carboxylesterases--detoxifying enzymes and targets for drug therapy. Curr Med Chem. 2006;13(9):1045-54. Review. PubMed PMID: 16611083. 19: Murthy VS, Frishman WH. Controlled beta-receptor blockade with esmolol and flestolol. Pharmacotherapy. 1988;8(3):168-82. Review. PubMed PMID: 2902602. 20: Singlas E, Fillastre JP. Pharmacokinetics of newer drugs in patients with renal impairment (Part II). Clin Pharmacokinet. 1991 May;20(5):389-410. Review. PubMed PMID: 1879096.